Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsConstruction in ProgressCurrent AssetsCurrent Deferred Tax AssetsCurrent Deferred Tax AssetsCurrent TaxesGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dr Reddys Laboratories (RDY) Assets (2017 - 2026)

Dr Reddys Laboratories has reported Assets over the past 10 years, most recently at $6.3 billion for Q1 2026.

  • For Q1 2026, Assets rose 11.32% year-over-year to $6.3 billion; the TTM value through Mar 2026 reached $6.3 billion, up 11.32%, while the annual FY2026 figure was $6.3 billion, 8.65% up from the prior year.
  • Assets for Q1 2026 was $6.3 billion at Dr Reddys Laboratories, up from $5.7 billion in the prior quarter.
  • Over five years, Assets peaked at $6.3 billion in Q1 2026 and troughed at $125.8 million in Q1 2023.
  • A 5-year average of $3.4 billion and a median of $4.7 billion in 2024 define the central range for Assets.
  • Biggest five-year swings in Assets: dropped 5.66% in 2023 and later skyrocketed 3608.33% in 2024.
  • Year by year, Assets stood at $133.4 million in 2022, then dropped by 5.66% to $125.8 million in 2023, then soared by 3608.33% to $4.7 billion in 2024, then rose by 22.0% to $5.7 billion in 2025, then rose by 11.32% to $6.3 billion in 2026.
  • Business Quant data shows Assets for RDY at $6.3 billion in Q1 2026, $5.7 billion in Q1 2025, and $4.7 billion in Q1 2024.